Recherche
-
Sequential mutational evaluation of CALR -mutated myeloproliferative neoplasms with thrombocytosis reveals an association between CALR allele burden evolution and disease progression
(British Journal of Haematology. vol. 188, n° 6, pp. 935–944, 2020)Article de revue -
Clinical and biological characterization of MPN patients harboring two driver mutations, a French intergroup of myeloproliferative neoplasms (FIM) study
(American Journal of Hematology. vol. 93, n° 4, pp. E84–E86, 2018-08)Article de revueAccès réservé -
Long-term follow-up of JAK2 exon 12 polycythemia vera: a French Intergroup of Myeloproliferative Neoplasms (FIM) study.
(Leukemia, 2020-07-21)Article de revue -
Genomic analysis of primary and secondary myelofibrosis redefines the prognostic impact of ASXL1 mutations: a FIM study.
(Blood Advances. vol. 5, n° 5, pp. 1442-1451, 2021-03-09)Article de revue -
JAK2 V617F polycythemia vera and essential thrombocythemia: dynamic clinical features associated with long-term outcomes.
(Blood Cancer Journal. vol. 12, n° 4, pp. 56, 2022-04-08)Article de revueLibre accès -
CALR-mutated patients with low allele burden represent a specific subtype of essential thrombocythemia: A study on behalf of FIM and GBMHM.
(American Journal of Hematology, 2024-02-25)Article de revueLibre accès